Technical Specifications Product Name XxRetaxX 20MG Scientific Research Name Retatrutide Development Identifier LY3437943 Research Description Triple GIP, GLP-1 and glucagon receptor agonist Compound Classification Synthetic modified peptide Research Quantity 20MG per vial Physical Form Lyophilized research material Primary Receptor Targets GIPR, GLP-1R and GCGR Receptor Classification Class B G-protein-coupled receptors Primary Signal Transduction Gs protein, adenylyl cyclase and cAMP Molecular Design Sequence-engineered and lipid-modified peptide Associated Research Feature Albumin association through fatty-acid modification Research Status Investigational compound Storage Form Dry lyophilized material Analytical Applications HPLC, LC-MS and modified-peptide stability research Intended Use Laboratory research only Molecular-Form Note: Retatrutide is a chemically modified peptide containing a peptide backbone, nonstandard structural elements, linker chemistry and a fatty-acid-containing modification
The standard escalation protocol Most providers prescribing Belmar semaglutide follow a gradual dose escalation that mirrors the FDA-approved Wegovy protocol, though individual adjustments are common: Weeks 1 through 4: 0.25 mg once weekly
This leads to a decrease in heart rate and dilation of blood vessels, ultimately lowering blood pressure
Side Effects Mild nausea occurs in some users
The care team is responsive, doctor visits happen every three months, and you don't need a video visit or labs to get started
